📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic supplier in decades.Nova’s Estelle Project in Alaska sits on a 35 km mineralized corridor hosting one of North America’s largest undeveloped gold systems, including a 5.2Moz SK-1300 pit-constrained resource. Chris discusses how the company’s latest world-class drill intercepts support strong project economics and why Nova still trades at a steep valuation discount relative to peers.👉 If you found this interview valuable, make sure to like the video, drop a comment with your thoughts or questions, and subscribe for more in-depth conversations with CEOs from emerging small-cap and microcap companies!Nova Minerals is a client of RedChip. To learn more about NVA and to read our full disclosure, visit: NVAinfo.com.#NovaMinerals #NVA #GoldStocks #CriticalMinerals #Antimony #MiningStocks #SmallCapStocks #GoldInvesting #AlaskaMining #DefenseProductionAct #USCriticalMinerals #GoldExploration

In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech

Jackpot Digital (OTCQB: JPOTF | TSXV: JJ) CEO Jake Kalpakian discusses how the company’s flagship Jackpot Blitz® platform is redefining casino poker economics through automation, recurring revenue, and global expansion.💡 Jackpot Digital represents an emerging opportunity at the intersection of technology, automation, and gaming, offering exposure to a rapidly growing segment of the global casino market.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Jackpot Digital is a client of RedChip. To learn more about JPOTF and to read our full disclosure, visit: JPOTFinfo.com.#JPOTF #JackpotDigital #SmallCapStocks #GamingStocks #CasinoTechnology #InvestorUpdate #ETG #DigitalGaming #RecurringRevenue #PokerTechnology

🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes.In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster onset, superior efficacy, and better safety.✅ The company’s unique positioning in acute exacerbations, a multi-billion-dollar market with no approved biologic therapies.✅ Key upcoming catalysts: topline data from Phase 2 acute studies in 1H 2026 and pharmacology results expected by early next year.✅ CNTB’s strong cash position ($71.8M) and runway into 2027, fully funding its U.S.-focused clinical milestones.✅ How its proven management team — responsible for bringing 16 drugs to FDA approval — is positioning the company for long-term growth.🎬 Watch now to learn why Connect Biopharma could be one of the most compelling small-cap biotech opportunities heading into 2026.Connect Biopharma is a client of RedChip. To learn more about CNTB and to read our full disclosure, visit: CNTBinfo.com.#CNTB #BiotechStocks #SmallCapStocks #AsthmaTreatment #COPD #HealthcareInnovation #Investing #BiotechInvesting #ClinicalTrials #NASDAQ

📊 FatPipe Networks (Nasdaq: FATN) — a pioneer in mission-critical networking and cybersecurity — is driving strong profitability and growth in the multi-billion-dollar SD-WAN and SASE markets.In this exclusive interview, Ragula Bhaskar, PhD, Co-Founder and CEO of FatPipe, discusses:✅ The company’s patented technology and 13 foundational networking patents✅ FatPipe’s 90%+ gross margins and subscription-based model with 36–60 month contracts✅ Channel-first sales strategy through 100+ reseller partners worldwide✅ FY25 financial highlights — $16.3M revenue and $2.0M net income (12.3% margin)✅ Expansion into Southeast Asia and Mexico amid rapid SD-WAN market growth (18.5% CAGR through 2030)💬 “We invented the space, we deliver the best support, and we’re scaling efficiently to grow top and bottom lines,” says Dr. Bhaskar.💡 Why Investors Should Watch:FatPipe operates at the intersection of four large and fast-growing markets — SD-WAN, Cybersecurity, Secure Access Service Edge (SASE), and Network Monitoring — expected to exceed $49B by 2030. The company’s strong IP moat, recurring revenue model, and capital efficiency position it as a rare “Rule of 40” small-cap software company.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!FatPipe is a client of RedChip. To learn more about FATN and to read our full disclosure, visit: FATNinfo.com.#FATN #SmallCapStocks #Cybersecurity #SDWAN #TechInvesting #Networking #InvestorRelations #SoftwareStocks #Profitability #FinancialNews

💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoquine in babesiosis (Oct 2025)• First patient cured of relapsing babesiosis using tafenoquine-based regimen• Three clinical trials underway, with data expected in 2026 to support a supplementary NDA• $245M peak U.S. market potential and ~$1.1B cumulative revenue opportunity through 2035• Commercial launch underway for ARAKODA® in malaria prevention as travel rebounds📈 Why This Matters for Investors:60 Degrees Pharmaceuticals is one of the smallest Nasdaq-listed biotechs with an FDA-approved product — and it’s pursuing a capital-efficient expansion into a large, underserved infectious disease market. With strong early efficacy signals, a clear regulatory roadmap, and increasing awareness of babesiosis nationwide, SXTP offers investors exposure to a high-upside, low-cost clinical advancement story.🧬 About the Company:60 Degrees Pharmaceuticals (Nasdaq: SXTP) develops and commercializes therapeutics for vector-borne diseases. Its lead product, ARAKODA®, is FDA-approved for malaria prevention and is being advanced into new indications including babesiosis.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.#SXTP #BiotechStocks #FDAApproval #PharmaInvesting #MicroCapStocks #InfectiousDiseases #Babesiosis #MalariaPrevention #HealthcareInnovation #Investors

🔋 Bimergen Energy (OTCQB: BESS) is emerging as a major player in the booming U.S. battery energy storage sector—and CFO Bob Brilon shares how the company is executing on a 2.0 GW pipeline backed by $250 million in equity commitments.With 2GW of BESS assets and a capital-efficient model designed to avoid shareholder dilution, Bimergen is positioned to become a cornerstone in the next generation of U.S. energy infrastructure.🗓️ Construction begins late 2025, operations expected in 2026.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bimergen Energy is a client of RedChip. To learn more about BESS and to read our full disclosure, visit: Bimergeninfo.com.#BESS #BatteryStorage #MicroCapStocks #EnergyStorage #AIInfrastructure #CleanEnergy #Bimergen #Investing #StockMarket #EnergyTransition

Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn• Nexalin’s vision for easy, drug-free, non-invasive support delivered at home• How the “Halo” headset fits into a virtual care workflow (physician-monitored)• Key takeaways from the company-referenced, peer-reviewed Alzheimer’s study• Commercial model: device + subscription (“razor/razor-blade” economics)• Near-term focus areas: mood/anxiety/sleep, TBI/PTSD, and early dementia• How management thinks about FDA strategy and global expansion🧠 Study reference (as discussed)• Nexalin references a peer-reviewed publication reporting statistically significant cognitive improvements and fMRI-observed connectivity changes in a mild Alzheimer’s cohort using a 40-Hz, 15 mA protocol, with no adverse events reported during the treatment period. 💼 Business model• Clinical setting: device placement with physicians; recurring revenue via single-use disposables/treatments• At-home: headset prescribed/ordered by a physician; subscription to access and remote monitoring via app/cloud• Goal: scale through a digital ecosystem that integrates diagnosis, treatment access, and physician oversight🔎 For investors• Thesis: simplified access, physician-monitored use at home, and recurring revenue economics could unlock a capital-efficient growth path if regulatory and clinical milestones are achieved.• Watchlist catalysts: additional study readouts, regulatory interactions/decisions, progress on U.S. pathway, international indication expansions, commercial pilots/rollouts, and updates on subscription adoption and reimbursement discussions.🔔 Drop your questions for Mark in the comments for future Q&A!Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Nexalin is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: NXLinfo.com.#Nexalin #NXL #MedTech #DigitalHealth #BrainHealth #Investing #Neurotechnology #Alzheimers #MentalHealth #AtHomeCare

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC innever-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressiveB-cell lymphomas. The company also advances CNS oncology programs via its subsidiary StarlightTherapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with globalpartners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanningJohns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value throughprecision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit LTRNinfo.com to learn more.

Foremost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the full potential of its projects, actively exploring in collaboration with Denison. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec.Foremost Clean Energy is a client of RedChip. Visit www.redchip.com/stocks/fmst to learn more.